Interferon-alpha therapy in polycythemia vera and essential thrombocythemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Essential thrombocythemia (ET) and polycythemia vera (PV) are chronic myeloid disorders marked by excessive blood cell production and increased risk of complications.
• Current treatments like phlebotomy and hydroxyurea have limitations, including thrombosis risk and potential for leukemia induction, and do not alter disease progression.

Purpose of the Study:

• To review the therapeutic activity and potential benefits of interferon-alpha for patients with essential thrombocythemia and polycythemia vera.
• To evaluate interferon-alpha's efficacy in managing hematologic parameters and disease-related symptoms.

Main Methods:

• Review of multiple small studies and single-arm trials investigating interferon-alpha in ET and PV.
• Analysis of reported hematologic, cytogenetic, and clinical outcomes associated with interferon-alpha therapy.

Main Results:

• Interferon-alpha demonstrated efficacy in controlling erythrocytosis and thrombocytosis in PV and ET.
• Beneficial effects on symptoms such as vasomotor symptoms, pruritus, and splenomegaly were reported.
• Emerging evidence suggests potential for cytogenetic remission and reversal of bone marrow fibrosis.

Conclusions:

• Interferon-alpha offers potential advantages over standard therapies, including a lack of known leukemogenic effects and the possibility of altering disease course.
• While promising, current data are insufficient for definitive recommendations, highlighting the need for randomized controlled trials comparing interferon-alpha with standard treatments.